- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Health Highlights: Oct. 21, 2016
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Lawmakers Question Leukemia Drug Price Increases
Two U.S. lawmakers want to know why a drug company increased the price of a leukemia drug by tens of thousands of dollars in recent years.
ARIAD Pharmaceuticals’ list price for a year’s supply of Iclusig, used to treat chronic myeloid leukemia, rose from $114,960 in 2012 to $198,732 in October 2016, according to data from Truven Health Analytics, the Associated Press reported.
On Thursday, Sen. Bernie Sanders, I-Vt., and Rep. Elijah Cummings, D-Md., the top Democrat on the House Oversight and Government Reform Committee, wrote ARIAD Pharmaceuticals and asked about the price increases.
“These outrageous sales tactics indicate that ARIAD is more concerned with its profit than with its patients,” they wrote, the AP reported.
The two lawmakers also said they are investigating whether ARIAD attempted to increase profits by changing pill dosages and quantities to charge insurers and patients more for less medicine.
Copyright © 2024 HealthDay. All rights reserved.